부산대학교 도서관

Anderson S; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Atkins P; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Bäckman P; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Cipolla D; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Clark A; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Daviskas E; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Disse B; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Entcheva-Dimitrov P; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Fuller R; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Gonda I; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.) igonda@respidex.com.; Lundbäck H; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Olsson B; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).; Weers J; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).

Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0421737 Publication Model: Print Cited Medium: Internet ISSN: 1521-0081 (Electronic) Linking ISSN: 00316997 NLM ISO Abbreviation: Pharmacol Rev Subsets: MEDLINE

Dwyer TJ; Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia tiffany.dwyer@sydney.edu.au.; Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia.; Daviskas E; Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia.; Zainuldin R; Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia.; Rehabilitation Dept, Ng Teng Fong General Hospital, Jurong Campus, NUHS Group, Singapore.; Physiotherapy, Health and Social Sciences Cluster, Singapore Institute of Technology, Singapore.; Verschuer J; Dept of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Sydney, Australia.; Eberl S; Dept of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Sydney, Australia.; Bye PTP; Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia.; Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.; Alison JA; Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia.; Sydney Local Health District, Sydney, Australia.

Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE

Dwyer TJ; Alison JA; McKeough ZJ; Daviskas E; Bye PT; Dwyer, Tiffany J; Alison, Jennifer A; McKeough, Zoe J; Daviskas, Evangelia; Bye, Peter T P

CHEST (CHEST), Apr2011; 139(4): 870-877. (8p)

Daviskas E; Anderson SD; Jaques A; Charlton B; Daviskas, Evangelia; Anderson, Sandra D; Jaques, Anna; Charlton, Brett

CHEST (CHEST), Apr2010; 137(4): 861-868. (8p)

Jaques A; Daviskas E; Turton JA; McKay K; Cooper P; Stirling RG; Robertson CF; Bye PT; Lesouëf PN; Shadbolt B; Anderson SD; Charlton B; Jaques, Anna; Daviskas, Evangelia; Turton, James A; McKay, Karen; Cooper, Peter; Stirling, Robert G; Robertson, Colin F; Bye, Peter T P; et al

CHEST (CHEST), Jun2008; 133(6): 1388-1396. (9p)

Anderson SD; Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia. Electronic address: sandra.anderson@sydney.edu.au.; Daviskas E; Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia. Electronic address: evangelia.daviskas@sydney.edu.au.; Brannan JD; Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia. Electronic address: john.brannan@health.nsw.gov.au.; Chan HK; Pharmaceutics, Pharmacology and Pharmaceutical Sciences, University of Sydney, Sydney, NSW 2006, Australia. Electronic address: kim.chan@sydney.edu.au.

Publisher: Elsevier Science Publishers, B.V Country of Publication: Netherlands NLM ID: 8710523 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8294 (Electronic) Linking ISSN: 0169409X NLM ISO Abbreviation: Adv Drug Deliv Rev Subsets: MEDLINE

Daviskas E; Anderson SD; Eberl S; Chan H; Young IH; Daviskas, E; Anderson, S D; Eberl, S; Chan, H K; Young, I H

CHEST (CHEST), Feb2001; 119(2): 414-421. (8p)

Dwyer TJ; Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia. tiffany.dwyer@sydney.edu.au.; Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia. tiffany.dwyer@sydney.edu.au.; Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia. tiffany.dwyer@sydney.edu.au.; Zainuldin R; Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia.; Rehabilitation Department, Ng Teng Fong General Hospital, Jurong Health Services, Jurong East, Singapore.; Health and Social Sciences, Academic Programme, Singapore Institute of Technology, Jurong East, Singapore.; Daviskas E; Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia.; Bye PT; Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia.; Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.; Alison JA; Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia.; Department of Physiotherapy, Royal Prince Alfred Hospital, Sydney, Australia.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968563 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2466 (Electronic) Linking ISSN: 14712466 NLM ISO Abbreviation: BMC Pulm Med Subsets: MEDLINE

Elkins MR; Royal Prince Alfred Hospital, Sydney, Australia.; Anderson SD; Royal Prince Alfred Hospital, Sydney, Australia.; Perry CP; Royal Prince Alfred Hospital, Sydney, Australia.; Daviskas E; Royal Prince Alfred Hospital, Sydney, Australia.; Charlton B; Pharmaxis Ltd, Sydney, Australia.

Publisher: Bentham Open Country of Publication: United Arab Emirates NLM ID: 101480481 Publication Model: eCollection Cited Medium: Print ISSN: 1874-3064 (Print) Linking ISSN: 18743064 NLM ISO Abbreviation: Open Respir Med J Subsets: PubMed not MEDLINE

Elkins MR; Royal Prince Alfred Hospital, Sydney, Australia.; Robinson P; Murdock Children's Research Institute and University of Melbourne, Royal Children's Hospital, Melbourne, Australia.; Anderson SD; Royal Prince Alfred Hospital, Sydney, Australia.; Perry CP; Royal Prince Alfred Hospital, Sydney, Australia.; Daviskas E; Royal Prince Alfred Hospital, Sydney, Australia.; Charlton B; Pharmaxis Ltd, Sydney, Australia.

Publisher: Bentham Open Country of Publication: United Arab Emirates NLM ID: 101480481 Publication Model: eCollection Cited Medium: Print ISSN: 1874-3064 (Print) Linking ISSN: 18743064 NLM ISO Abbreviation: Open Respir Med J Subsets: PubMed not MEDLINE